Tevogen Bio Expands AI Collaboration with Microsoft to Accelerate Drug Development

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference - Microsoft (NASDAQ:MSFT), Tevogen Bio Holdings (NASDAQ:TVGN)

WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Company" or "Tevogen Bio") TVGN, a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commitment to patient equity. By applying ML through Tevogen.AI, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. The discussion featured Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare at Microsoft MSFT, and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, who shared their vision for how AI is revolutionizing drug development and healthcare delivery. Accelerating Drug Discovery In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a computational task that previously may have taken "thousands of years" using traditional approaches was completed in a matter of months thanks to AI-powered tools. These breakthroughs, Dr. Rhew noted, illustrate a paradigm shift in what is now possible in the pharmaceutical research and development process. The Rise of Generative AI and Multimodal Data Both speakers emphasized that while generative AI has garnered widespread attention, next-generation approaches extend beyond simply creating text or images. According to Dr. Rhew, organizations are increasingly deploying multimodal data AI, which processes data from diverse sources, such as imaging, genomics, and electronic health records, to reveal novel insights. Generative AI then serves as a powerful query engine on top of these "foundation models," enabling seamless interpretation and conversion of complex data into clinically relevant results and formats. Ensuring Data Quality, Privacy, and Responsible AI Speaking to Tevogen Bio's AI developments, Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, highlighted, "We are creating curated datasets, supported by wet-lab research, to fuel the creation of reliable foundational AI models." Dr. Rhew echoed the need for "clean" and "annotated" datasets, stating, "AI is like a powerful engine. It can take us anywhere, but it needs clean, curated data as fuel. Crude data won't work; it must be refined and properly annotated to be useful." Both speakers also stressed the importance of strong data governance and privacy-preserving techniques, such as federated learning and confidential compute, which enable secure collaboration on sensitive datasets without exposing proprietary information or intellectual property. Dr. Rhew underscored that responsible AI requires bias mitigation, transparency, and continuous oversight. Mr. Mehta commended Microsoft's commitment to these principles, stating that responsible development practices are vital to ensuring equitable and safe adoption of AI technologies in healthcare. "AI is the next industrial revolution and could be humanity's greatest leap yet. I commend efforts similar to Stargate for their investment in forward-thinking and transformative technologies," said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. "Drug development will undoubtedly improve with the power of AI, but the key is to seamlessly bridge medical science and technology. As a biotech focused on pioneering through AI, we remain committed to advancing affordable medical innovation." About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 [email protected] A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f6d82a7-ae1f-40ac-888f-dbd580e3af4b MSFTMicrosoft Corp$446.350.03%Overview Rating:Good62.5%Technicals Analysis1000100Financials Analysis400100WatchlistOverviewTVGNTevogen Bio Holdings Inc$1.446.67%TVGNWTevogen Bio Holdings Inc$0.0775-%Market News and Data brought to you by Benzinga APIs

Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

WARREN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Company" or "Tevogen Bio") (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers, today announced key insights from its recent fireside chat during the J.P. Morgan Healthcare Conference. Utilizing artificial intelligence (AI) and machine learning (ML) has been critical for Tevogen Bio, given its core commitment to patient equity. By applying ML through Tevogen.AI, the company has already achieved notable cost and time efficiencies, developments that could translate directly into savings for patients. The discussion featured Dr. David Rhew, Global Chief Medical Officer & VP of Healthcare at Microsoft (Nasdaq: MSFT), and Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, who shared their vision for how AI is revolutionizing drug development and healthcare delivery. Accelerating Drug Discovery In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a computational task that previously may have taken "thousands of years" using traditional approaches was completed in a matter of months thanks to AI-powered tools. These breakthroughs, Dr. Rhew noted, illustrate a paradigm shift in what is now possible in the pharmaceutical research and development process. The Rise of Generative AI and Multimodal Data Both speakers emphasized that while generative AI has garnered widespread attention, next-generation approaches extend beyond simply creating text or images. According to Dr. Rhew, organizations are increasingly deploying multimodal data AI, which processes data from diverse sources, such as imaging, genomics, and electronic health records, to reveal novel insights. Generative AI then serves as a powerful query engine on top of these "foundation models," enabling seamless interpretation and conversion of complex data into clinically relevant results and formats. Ensuring Data Quality, Privacy, and Responsible AI Speaking to Tevogen Bio's AI developments, Mittul Mehta, Chief Information Officer and Head of Tevogen.AI, highlighted, "We are creating curated datasets, supported by wet-lab research, to fuel the creation of reliable foundational AI models." Dr. Rhew echoed the need for "clean" and "annotated" datasets, stating, "AI is like a powerful engine. It can take us anywhere, but it needs clean, curated data as fuel. Crude data won't work; it must be refined and properly annotated to be useful." Both speakers also stressed the importance of strong data governance and privacy-preserving techniques, such as federated learning and confidential compute, which enable secure collaboration on sensitive datasets without exposing proprietary information or intellectual property. Dr. Rhew underscored that responsible AI requires bias mitigation, transparency, and continuous oversight. Mr. Mehta commended Microsoft's commitment to these principles, stating that responsible development practices are vital to ensuring equitable and safe adoption of AI technologies in healthcare. "AI is the next industrial revolution and could be humanity's greatest leap yet. I commend efforts similar to Stargate for their investment in forward-thinking and transformative technologies," said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. "Drug development will undoubtedly improve with the power of AI, but the key is to seamlessly bridge medical science and technology. As a biotech focused on pioneering through AI, we remain committed to advancing affordable medical innovation." About Tevogen Bio Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Bio Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen Bio has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen Bio's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f6d82a7-ae1f-40ac-888f-dbd580e3af4b

What's Going On With Tevogen Bio Stock Today? - Tevogen Bio Holdings (NASDAQ:TVGN)

Tevogen will integrate Microsoft's AI tools to help expand the company's pre-clinical pipeline. Tevogen Bio Holdings Inc TVGN shares are trading higher Monday after the company announced an expanded AI collaboration with Microsoft Corp MSFT. What Happened: After the market close on Friday, Tevogen Bio announced a broadening of its relationship with Microsoft to expand its AI-focused collaboration and build its PredicTcell technology. The expanded collaboration is expected to use Microsoft's AI, cloud capabilities and health and life sciences domain expertise to accelerate Tevogen Bio's target identification and pre-clinical processes. "As we expand our AI efforts, this broader relationship with Microsoft represents a key milestone in our ongoing journey to revolutionize immunotherapy," said Mittul Mehta, CIO of Tevogen Bio and Head of Tevogen.AI. "Through deeper collaboration with Microsoft domain experts, we will further harness the power of AI to bring more precise and personalized treatments to patients at an accelerated pace." Tevogen said it will integrate Microsoft's AI tools into Tevogen.AI to help expand the company's pre-clinical pipeline and develop algorithms to decode HLA-T cell interactions. The company noted that it will also investigate potential treatments for Human Papillomavirus (HPV). Tevogen Bio is a clinical-stage specialty immunotherapy company using CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for the treatment of infectious diseases, cancers and neurological disorders. PredicTcell is the company's proprietary technology designed for predictive precision T cell targeting. See Also: DeepSeek Jitters Shatter US Tech Stocks, Wipe Out $1.2 Trillion On Wall Street: Analyst Eyes Four Chinese Giants Set To Benefit TVGN Price Action: Tevogen Bio shares were up 15.6% at $1.56 at the time of publication Monday, according to Benzinga Pro. This illustration was generated using artificial intelligence via Midjourney. Market News and Data brought to you by Benzinga APIs

Tevogen Bio Stock Soars on Expanded Team-Up with Microsoft

Shares of Tevogen Bio surged after the company said it has broadened its relationship with Microsoft in an AI-focused collaboration to develop the biotech's proprietary technology. The stock was up 52% at $2.06 in premarket trading on Monday. Shares were trading at $7.58 this time a year ago. The Warren, N.J., company said after the market closed last week that Microsoft is using its AI and cloud capabilities to help build Tevogen's PredicTcell technology, which is designed for predictive precision T-cell targeting. Microsoft's health and life sciences domain expertise should accelerate Tevogen's target identification and pre-clinical processes, the company said.